● Recruiting

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

Condition: Solid Tumor · HNSCC · RCC · Sponsor: SparX Biotech(Jiangsu) Co., Ltd.

PhasePhase 1

Planned participants232

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.

This description comes directly from the study's public registry record.

Talk to the study team

SparX Biotech · 847-739-6251 · SPX-303@sparxbio.com

Always discuss trial participation with your own doctor first.

Locations (4)

Mayo Clinic Arizona	Phoenix, Arizona, United States	Recruiting
HonorHealth Research and Innovation Institute	Scottsdale, Arizona, United States	Recruiting
Mayo Clinic Florida	Jacksonville, Florida, United States	Recruiting
Mayo Clinic Rochester	Rochester, Minnesota, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06259552